Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/…
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…